MOTORK
15.11.2021 08:32:10 CET | Business Wire | Press release
MotorK, plc (AMS: MTRK) (“MotorK” or “the Group"), a leading SaaS provider for the automotive retail industry in the EMEA region, today reported financial results for the third quarter ended September 30, 2021.
Third Quarter 2021 and Other Recent Financial and Operating Highlights:
- Revenue of €8.1 million in Q3 2021, up 86% compared to Q3 2020;
- Revenue of €20.9 million for the first 9 months of 2021, up 54% compared to the same period in 2020;
- Adjusted EBITDA was €1.4 million in Q3 2021, representing an adjusted EBITDA margin of 17.5%;
- Adjusted EBITDA was €1.8 million for the first 9 months of 2021, representing an adjusted EBITDA margin of 8.6%;
- Revenue and adjusted EBITDA growth driven by the strong performance of SaaS platform revenue in 2021 YTD, which was up 73% year-on-year;
- Total R&D spend reached €2.0 million in Q3 2021, up 53% compared to €1.3 million R&D spend in Q3 2020, leading to a total of €5.4 million, or 26% of the revenue, for the first 9 months of 2021;
- Revenue for FY 2021 expected to come at the top end of the €25-27m guidance range, in light of current results.
“In the third quarter, MotorK continued to deliver solid top-line growth driven by the strong performance of our cloud-based SaaS platform that offers a comprehensive suite of products to support the full vehicle lifecycle and the entire customer journey,” commented Marco Marlia, CEO of MotorK. “Our business continues to progress at a fast pace, and we are very satisfied with the performance we delivered this quarter. Looking ahead, we will continue to focus on our growth strategy focused on innovation to further strengthen our value proposition and SaaS offering expansion, as evidenced by our healthy level of R&D investment which was up significantly compared to the prior year. We will also continue to actively identify and leverage organic and inorganic opportunities to win new customers and roll-out additional offerings into new markets and geographies.”
FINANCIAL HIGHLIGHTS
Key Figures
Key figures |
Q3 '21 |
Q3 '20 |
y.o.y.
|
YTD '21 |
YTD '20 |
y.o.y.
|
||||||
€'000 |
||||||||||||
Revenue |
8,089 |
4,359 |
86% |
20,870 |
13,547 |
54% |
||||||
Adjusted EBITDA* |
1,411 |
(212) |
- |
1,749 |
(1,415) |
- |
||||||
Adjusted EBITDA margin |
17.5% |
-5% |
22% |
8% |
-10% |
19% |
*Adjusted EBITDA is defined as EBITDA as adjusted for stock option costs and certain income and costs, which are expected to occur infrequently, and that management considers not reflective of ongoing operational activities. Adjusted EBITDA Margin is defined as Adjusted EBITDA divided by Revenue.
The Group generated €8.1 million in revenue for the quarter, up 86% compared to the prior year, driven by a strong performance of its SaaS platform, across both the WebSparK and LeadSparK platforms. Revenue this quarter was positively impacted by delivery to a major OEM client in Germany.
Adjusted EBITDA for the quarter was €1.4 million, compared to a €212,000 loss in 2020. The Adjusted EBITDA margin was strong at 17.5%, benefitting from SaaS-driven operating leverage, despite continued investments in R&D and innovation.
Revenue
Revenue by product and service line
The table below shows the Group’s revenue broken down by product and service line for Q3 2021 and Q3 2020, and for the nine-month periods ended September 30, 2021 and September 30, 2020.
Revenue by product and service line |
Q3 '21 |
Q3 '20 |
y.o.y.
|
YTD '21 |
YTD '20 |
y.o.y.
|
||||||
€'000 |
||||||||||||
SaaS platform revenue |
5,738 |
2,364 |
143% |
12,294 |
7,091 |
73% |
||||||
Digital Marketing revenue |
1,799 |
1,591 |
13% |
5,840 |
5,060 |
15% |
||||||
Other revenue |
552 |
404 |
37% |
2,736 |
1,396 |
96% |
||||||
Total |
8,089 |
4,359 |
86% |
20,870 |
13,547 |
54% |
With respect to the product and service lines of the Group’s business, the Group’s revenue is derived primarily from its SaaS platform. Revenue generated from the SaaS platform amounted to €5.7 million in the third quarter of 2021, an increase of about €3.3 million or 143% compared to the prior year period, and €12.3 million for the nine-month period ended September 30, 2021, an increase of about €5.2 million, or 73%, compared to the nine-month period ended September 30, 2020.
Research & Development Costs and Investments
Set forth below are the breakdown of the Group’s total R&D spend in absolute terms and as a percentage of the Group’s total revenue for Q3 2021 and Q3 2020, and for the nine-month periods ended September 30, 2021 and September 30, 2020.
R&D spend |
Q3 ‘21 |
Q3 ‘20 |
y.o.y.
|
YTD ‘21 |
YTD ‘20 |
y.o.y.
|
|||||||
€’000 (except percentages) |
|||||||||||||
Total R&D spend |
2,026 |
1,320 |
54% |
5,351 |
3,688 |
45% |
|||||||
- of which capitalised |
(800) |
(689) |
16% |
(2,210) |
(1,996) |
11% |
|||||||
- of which expensed in the income statement |
1,226 |
631 |
94% |
3,141 |
1,692 |
86% |
|||||||
Total R&D spend as a percentage of Group total Revenue |
25% |
30% |
-5% |
26% |
27% |
-2% |
|||||||
As part of its growth strategy, MotorK has continued to invest in R&D to develop innovative solutions for its customers and expand the capabilities of its SaaS platform. R&D spend reached €2 million in Q3 2021 and €5.4 million for the first 9 months of 2021, up 54% and 45% respectively compared to the same periods in 2020.
OUTLOOK
MotorK expects FY 2021 revenue to come at the top end of the €25-27 million guidance range, in light of current results.
Conference Call Information
Marco Marlia (CEO) and Andrea Servo (CFO) will host a conference call for analysts and investors at 5:00 pm CET to discuss the 2021 third quarter results. A live webcast of the conference call and related earnings materials can be accessed on MotorK’s Investor Relations website (investors.motork.io/). A replay of the webcast will be available through the same link on the website following the conference call.
About MotorK Plc
MotorK (AMS: MTRK) is a leading software as a service (“SaaS”) provider for the automotive retail industry in the EMEA region, with over 300 employees and eight offices in seven countries (Italy, Spain, France, Germany, Portugal, the UK and Israel). MotorK empowers car manufacturers and dealers to improve their customer experience through a broad suite of fully integrated digital products and services. MotorK provides its customers with an innovative combination of digital solutions, SaaS cloud products and the largest R&D department in the automotive digital sales and marketing industry in Europe. MotorK was founded in Italy in 2010 and has been recognised by multiple organisations as one of the fastest growing tech companies in Europe – including Euronext TechShare, Tech Tour 50, Technology Fast 500 EMEA and the FT 1000. For more information, please visit: www.motork.io .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211114005325/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Restylane® Contour™ for the Correction of Temple Hollowing23.3.2026 07:00:00 CET | Press release
The United States (U.S.) Food and Drug Administration (FDA) has approved Restylane Contour* for the correction of temple hollowing, expanding its use beyond cheek augmentation and midface contour deficiencies to support overall facial balance and harmony1-3 The approval is based on clinical data showing Restylane Contour, part of Galderma’s versatile portfolio of hyaluronic acid injectables, delivers natural-looking results lasting for up to 18 months and high patient satisfaction1,2 This follows the recent U.S. FDA approval for Restylane Lyft™ for the enhancement of the chin profile and the debut of the ‘Wake Up to Restylane’ campaign in the U.S., highlighting Galderma’s commitment to continuing to evolve this versatile portfolio to meet emerging and diverse needs, including the desire for effortless, ‘wake‑up‑ready’ beauty4 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the U.S. FDA has approved Restylane Contour for the correction of temple hol
Paving the Way for Real‑Time Earth Observation: Space Compass and SWISSto12 Sign Contract for First Commercial GEO Optical Data Relay Satellite23.3.2026 05:00:00 CET | Press release
Space Compass Corporation (“Space Compass”) and SWISSto12 SA (“SWISSto12”) announced today that they have executed a procurement contract for the first GEO optical data relay satellite. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260320584108/en/ (From Left to Right): Julie Pignon, Legal Counsel, SWISSto12; 倉田 るり子 (Ruriko Kurata), Legal Counsel, Space Compass; 小松 大実 (Hiromi Komatsu), Co-CEO, Space Compass; 田中 良太 (Ryota Tanaka), Engineering Director, Space Compass; Emile de Rijk, CEO, SWISSto12; Fredrik Gustavsson, Chief Financial and Strategy Officer, SWISSto12. This agreement represents a major milestone toward the realization of Space Compass’s optical data relay service. With high-speed, high-capacity optical data relay service, Space Compass aims to transform Earth Observation from just a tracking record into a real-time decision-making tool. For SWISSto12, the contract represents further validation of the company’s a
Andersen Consulting styrker sit cybersikkerhedstilbud gennem samarbejde med Trillium Information Security Systems21.3.2026 02:16:00 CET | Pressemeddelelse
Andersen Consulting udbygger sine kompetencer inden for teknologi og risikostyring gennem en samarbejdsaftale med Trillium Information Security Systems (TISS), et cybersikkerhedsfirma. Med en tilstedeværelse i Canada og Pakistan leverer TISS omfattende cybersikkerhedsløsninger til organisationer inden for finans, telekommunikation og den offentlige sektor. Virksomhedens team tilbyder et bredt udvalg af ydelser, herunder sikkerhedsvurderinger, managed security operations, red team-tjenester, digital efterforskning og hændelsesrespons samt GRC-rådgivning. Med næsten to årtiers erfaring leverer TISS adaptive, efterretningsdrevne forsvarsmekanismer, der hjælper kunder med at forudse og reagere på cybertrusler, der er i konstant udvikling. "Hos TISS arbejder vi på at skabe et mere sikkert digitalt miljø ved at give organisationer mulighed for at operere sikkert og med selvtillid," udtalte Mahir Mohsin Sheikh, administrerende direktør for TISS. "Vores samarbejde med Andersen Consulting giver
Andersen Consulting udvider sin teknologiplatform i Frankrig20.3.2026 17:28:00 CET | Pressemeddelelse
Andersen Consulting udvider sit udbud inden for digital transformation med en samarbejdsaftale med Teolia Consulting, et fransk firma, der specialiserer sig i projekt- og produktstyring, cloud-platformsudvikling, datatransformation samt implementering og brug af Atlassian-pakken. Teolia Consulting blev grundlagt i 2014 og hjælper organisationer med at opnå digital performance, fra agile metoder til løsninger, der reducerer lanceringstiden. Virksomhedens ekspertise består i at levere integrerede strategier, der bringer teknologi og organisatorisk forandring i overensstemmelse. Virksomheden arbejder på tværs af brancher, herunder inden for bank- og finanssektoren, forsikring, mode og detailhandel, og hjælper kunder med at få større robusthed og accelerere deres digitale modenhed. "Hos Teolia Consulting mener vi, at ægte transformation opstår, når teknologi og mennesker udvikler sig sammen," sagde Lucienne Jacquet, der er administrerende partner i Teolia. "Ved at samarbejde med Andersen C
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting20.3.2026 15:00:00 CET | Press release
- New, late-breaking 54-week data for povorcitinib in hidradenitis suppurativa (STOP-HS1 & STOP-HS2) to be highlighted - Featured abstracts for ruxolitinib cream (Opzelura®) and povorcitinib include multiple ePosters in atopic dermatitis, hidradenitis suppurativa and vitiligo Incyte (Nasdaq:INCY) today announced that data from key programs in its Inflammation and Autoimmunity (IAI) franchise will be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, to be held March 27 – 31, 2026, in Denver. “At AAD 2026, we are presenting late‑breaking 54-week results from the Phase 3 STOP‑HS program evaluating povorcitinib in hidradenitis suppurativa (HS),” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation and Autoimmunity, Incyte. “These data provide longer term evidence of the safety and efficacy of povorcitinib in HS patients and further strengthen the significant growth potential of our Inflammation and Autoimmunity franchise.” Details on key data presentation
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
